T1	intervention 226 252	doxorubicin plus docetaxel
T2	control 268 301	doxorubicin plus cyclophosphamide
T3	total-participants 314 317	627
T4	eligibility 318 342	women with breast cancer
T5	outcome 473 475	FN
T6	iv-bin-percent 488 493	40.8%
T7	iv-bin-abs 495 498	126
T8	intervention-participants 499 502	311
T9	cv-bin-percent 520 524	7.1%
T10	cv-bin-abs 526 528	22
T11	control-participants 529 532	316
T12	outcome 804 806	FN
T13	iv-bin-abs 865 867	85
T14	cv-bin-abs 881 883	70
T15	outcome 1072 1082	risk of FN
T16	iv-bin-percent 1084 1089	83.3%
T17	cv-bin-percent 1139 1144	32.8%
